DisclosureWe earn commission on partner links; ranking is set by our published methodology — not advertisers.
For the first time, Medicare pays for weight-loss GLP‑1s: $50 a month for Wegovy, Foundayo, or the Zepbound KwikPen. But the eligibility rules run backwards from what most people expect, and the covered-forms list has a trap. Here is the whole program, from the CMS rules — not the headlines.
Every other coverage fight in this category rewards having a qualifying diagnosis. The Bridge inverts that: it exists to cover the people Part D has always excluded — those seeking a GLP-1 for weight loss alone. If you have type 2 diabetes, moderate-to-severe obstructive sleep apnea, or fatty liver disease, you already have an on-label route (Ozempic or Mounjaro for diabetes, Zepbound’s OSA indication, and so on) that your plan is expected to cover normally — so CMS routes you there, not through the Bridge. That is why being “healthier on paper” is, for once, what qualifies you.
| Drug | Covered forms | NOT covered |
|---|---|---|
| Wegovy | Weekly injection AND the daily tablet | — |
| Foundayo | Daily tablet (orforglipron) | — |
| Zepbound | KwikPen only | Single-dose pens, LillyDirect vials |
| Everything else | — | Ozempic, Mounjaro, Rybelsus, compounded GLP-1s |
The Zepbound line is the trap: the cheap LillyDirect vials people know from cash-pay are not in the program — only the KwikPen presentation. If your pharmacy runs the claim on the wrong NDC, it will reject.
The $50 sits outside your normal Part D benefit: it does not count toward your deductible and does not accumulate toward the annual out-of-pocket cap that triggers catastrophic coverage. And the program is an 18-month demonstration — July 1, 2026 to December 31, 2027 — with no guaranteed continuation. If a GLP-1 works for you, plan for the possibility that in 2028 you are back to cash-pay pricing (Foundayo from ~$149, Wegovy pill $149–$299, Zepbound vials $349–$499) or a coverage fight.
Three steps: confirm you have Part D or Medicare Advantage drug coverage; have your prescriber verify you meet the criteria (no T2D, no moderate-to-severe OSA, no fatty liver) and submit the prior authorization; then fill at a network pharmacy for the flat $50. If you are already getting a GLP-1 paid by your plan for any reason, CMS says to stay on your plan’s coverage — the Bridge is not for switching. KFF estimates roughly 3.8 million beneficiaries qualify, so expect prior-auth queues in the first months. Denied anyway? Our appeal-letter generator covers Medicare GLP-1 denials.